Peer-reviewed research from our team

Published research from the nuclear medicine team.

Peer-reviewed publications by Dr. Ishita B. Sen, Dr. Dharmender Malik and the Department of Nuclear Medicine team at Fortis Memorial Research Institute, Gurugram — published across Annals of Nuclear Medicine, British Journal of Radiology, and Clinical Nuclear Medicine.

Peer-reviewed papers

Different journals

First authors from team

Read the publications Patient case studies

Why this matters · for patients

When you trust your treatment to a team, it helps to know they're also publishing what they learn — for peer review by the global nuclear medicine community.

View all on PubMed →

Research portfolio

What we've published, and what it means for you.

Each paper below is a peer-reviewed publication — meaning it was independently reviewed by two or more nuclear medicine experts at international journals before being published. Each is indexed on PubMed, the US National Library of Medicine's medical research database.

We've included a plain-language summary of each paper for patients and referring physicians, alongside the standard journal citation and a direct link to the full record on PubMed. Where a paper relates to a treatment we offer, we've linked the relevant treatment page as well.

In prostate cancer

2 publications

Annals of Nuclear Medicine · 2021 Vol 35(7):794–810 PMID 34059998

Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy.

☆

Lead authorDr. Sen

Authors Sen I, Thakral P, Tiwari P, Pant V, Das SS, Manda D

Many men with advanced prostate cancer reach a point where standard hormone and chemotherapy treatments stop working. This paper studied whether Actinium-225 PSMA-617 — a targeted alpha radioligand therapy — could help patients in this situation. The team treated patients who had already progressed despite taxane chemotherapy.

★ Key findings

Ac-225 PSMA targeted alpha therapy produced meaningful disease control in patients who had exhausted standard chemotherapy options
The team reported on response patterns, side effect management, and dosimetry — clinically essential information for guiding this therapy in real-world practice
One of the foundational Indian publications on Ac-225 PSMA in the post-chemo setting

Read full paper on PubMed Related treatment: Alpha PSMA

Clinical Nuclear Medicine · 2021 PMID 34524171

Upfront use of 177Lu-labeled PSMA radioligand therapy and treatment response assessment in treatment-naive prostate cancer.

☆

Lead authorDr. Malik

Authors Malik D, Sen IB, Thakral P, Das SS, Manda D, Cb V

For most patients with metastatic prostate cancer, early androgen deprivation therapy (ADT) is the standard first treatment — but ADT often impairs quality of life. This paper presents a case where the team used 177Lu-PSMA-617 radioligand therapy as the very first treatment in a patient with treatment-naive oligometastatic prostate cancer. The patient showed excellent response to a single dose of Lu-PSMA-617 — a meaningful proof-of-concept for upfront Lu-PSMA as an alternative or delay strategy to ADT.

★ Key findings

A single dose of Lu-PSMA-617 produced an excellent treatment response in a treatment-naive oligometastatic prostate cancer patient
Demonstrates the feasibility of Lu-PSMA as upfront / first-line therapy — potentially delaying or replacing androgen deprivation in selected patients
Quality-of-life implications: patients can postpone the side effects of long-term hormone therapy while achieving disease control

Read full paper on PubMed Related treatment: Lu-PSMA See the related case study

In neuroendocrine tumours

1 publication

British Journal of Radiology · 2021 Vol 94(1126):20210403 PMID 34357794

Dosimetric analyses of intra-arterial vs intravenous 177Lu-DOTATATE in patients with liver-dominant well-differentiated neuroendocrine tumours.

☆

Lead authorDr. Thakral

Authors Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D

In patients whose neuroendocrine tumours are concentrated mostly in the liver, the standard PRRT approach — intravenous Lu-177 DOTATATE — distributes radiation throughout the whole body. This paper investigated whether delivering the same therapy directly into the artery supplying the liver (intra-arterial administration) would concentrate more radiation at the tumour and less in healthy tissue. The team performed detailed dosimetric measurements comparing the two routes.

★ Key findings

Intra-arterial Lu-DOTATATE delivered substantially higher radiation doses to liver tumour compared to the standard intravenous route
The technique offers a meaningful option for patients with liver-dominant neuroendocrine metastases who would otherwise plateau on standard IV PRRT
Pioneering work in this delivery technique within India — combines our PRRT and TARE infrastructure

Read full paper on PubMed Related treatment: PRRT Related treatment: TARE See related case study

The research team

Three first authors. One nuclear medicine team.

Across these three papers, three different members of our team appear as first author — reflecting a research culture where leadership in publication is shared rather than concentrated. Every paper involved the broader department.

Dr. Ishita B. Sen

Director, Department of Nuclear Medicine, FMRI

First author · Ann Nucl Med 2021 — Ac-225 PSMA in mCRPC after chemo

View profile

Dr. Dharmender Malik

Senior Consultant, Department of Nuclear Medicine, FMRI

First author · Clin Nucl Med 2021 — upfront Lu-PSMA in treatment-naive prostate cancer

View profile

Dr. Parul Thakral

Consultant, Department of Nuclear Medicine, FMRI

First author · Br J Radiol 2021 — intra-arterial Lu-DOTATATE for liver NET

View profile

More publications in preparation.

Additional research publications and conference abstracts from our team will be added to this page as they are published and indexed. For the most current full list, search "Fortis Memorial Research Institute" on PubMed directly.

Patient case studies

Read about real patient outcomes at our centre.

Alongside our peer-reviewed publications, we maintain a library of anonymised patient case studies — documented examples of how specific therapies have performed in specific clinical situations. Useful for prospective patients and referring physicians considering radioligand therapy options.

View case studies